Business Overview
Nutriband Inc. develops transdermal pharmaceutical products incorporating its Aversa abuse-deterrent technology into already-approved drugs, requiring FDA approval before commercialization. The company also operates Pocono Pharmaceuticals, a contract development and manufacturing organization for transdermal, topical, and nutraceutical products, and Active Intelligence, which manufactures activated kinesiology tape. During the three months ended April 30, 2026, the company generated revenue of $433,399 from sale of goods, down from $667,432 in the prior year period.
Segment Performance
The company reports revenue by type and geography rather than business segments in the filing provided. For the three months ended April 30, 2026, total revenue of $433,399 consisted entirely of sale of goods, with all revenue derived from United States customers. This represents a decrease from the prior year period ended April 30, 2025, which generated total revenue of $667,432, also entirely from sale of goods in the United States. The company recorded a net loss of $1,241,956 for the three months ended April 30, 2026, compared to $1,388,869 for the prior year period.
Forward Guidance
Management states it "believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company's ability to continue operations as a going concern." The filing notes that the results for the three months ending April 30, 2026 "are not necessarily indicative of the results to be expected for the full year."
Key Risk Factors
The company has generated operating losses since inception and relies on equity financing and debt to fund operations, raising going concern uncertainties. Revenue is highly concentrated with four customers representing 69% of total revenues (Customer A 25%, Customer B 20%, Customer C 14%, Customer D 10%). The company faces regulatory risk as it requires FDA approval for its pharmaceutical products before commercialization. The company is dependent on raising additional capital to fund ongoing research and development of its Aversa product.
